Our office provides a comprehensive Dementia Evaluation and potential Treatment for early Alzheimer Disease with the recently approved Amyloid Monoclonal Antibody from the pharmaceutical company, EISAI Inc., called LECANEMAB OR LEQEMBI. Medicare is currently covering eighty percent cost of this medication.
To be evaluated, please contact our Dementia Clinic at 650-808-0180 and make an appointment. The evaluation of Dementia and qualification for LECANEMAB involves at least two visits to our clinic with our Board Certified Geriatricians and an amyloid PET CT SCAN or SPINAL FLUID ANALYSIS, which could be performed at your preferred clinic.
If you qualify for this treatment, we will start the LEQEMBI protocol in collaboration with the local community infusion centers approved by EISAI Pharmaceutical. LECANEMAB treatment involves two infusions monthly while you are under the close supervision of our clinic. You also need to undergo five MRIs during the one year course of the treatment.
To be evaluated, please contact our Dementia Clinic at 650-808-0180 and make an appointment. The evaluation of Dementia and qualification for LECANEMAB involves at least two visits to our clinic with our Board Certified Geriatricians and an amyloid PET CT SCAN or SPINAL FLUID ANALYSIS, which could be performed at your preferred clinic.
If you qualify for this treatment, we will start the LEQEMBI protocol in collaboration with the local community infusion centers approved by EISAI Pharmaceutical. LECANEMAB treatment involves two infusions monthly while you are under the close supervision of our clinic. You also need to undergo five MRIs during the one year course of the treatment.